4D Molecular Therapeutics (NASDAQ:FDMT) Releases Earnings Results, Misses Estimates By $0.10 EPS

4D Molecular Therapeutics (NASDAQ:FDMT) issued its earnings results on Friday. The company reported ($0.90) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.80) by ($0.10), Zacks reports.

4D Molecular Therapeutics Stock Up 1.1 %

FDMT stock opened at $4.53 on Friday. 4D Molecular Therapeutics has a twelve month low of $4.20 and a twelve month high of $36.25. The stock’s 50 day moving average is $5.22 and its 200-day moving average is $8.59. The firm has a market capitalization of $209.41 million, a PE ratio of -1.59 and a beta of 2.81.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on FDMT. HC Wainwright reissued a “buy” rating and issued a $36.00 price target on shares of 4D Molecular Therapeutics in a research note on Monday, February 10th. Morgan Stanley decreased their price target on 4D Molecular Therapeutics from $8.00 to $6.00 and set an “underweight” rating for the company in a research note on Monday, January 13th. Weiss Ratings reissued a “sell (d-)” rating on shares of 4D Molecular Therapeutics in a research note on Wednesday, February 19th. BMO Capital Markets lowered 4D Molecular Therapeutics from an “outperform” rating to a “market perform” rating and cut their target price for the company from $40.00 to $15.00 in a research report on Monday, January 13th. Finally, Royal Bank of Canada cut their target price on 4D Molecular Therapeutics from $40.00 to $39.00 and set an “outperform” rating on the stock in a research report on Thursday, November 14th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and seven have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $32.13.

About 4D Molecular Therapeutics

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.